+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

New model for drug development needed in leukaemia



New model for drug development needed in leukaemia



Lancet. Oncology 7(11): 893




Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 049688701

Download citation: RISBibTeXText

PMID: 17099982

DOI: 10.1016/s1470-2045(06)70925-1


Related references

Hairy-cell leukaemia as a model for drug development. Best Practice and Research. Clinical Haematology 16(1): 83-89, 2003

Nelarabine: new drug. T-lymphoblastic leukaemia/lymphoma: more evaluation needed. Prescrire International 18(99): 3-5, 2009

The Role of Drug Exposure in Clinical Development: To What Extent Is Pharmacokinetic Assessment Needed in a Drug Development Programme?. Clinical Pharmacokinetics 54(10): 985-987, 2015

Progress in TB drug development and what is still needed. Tuberculosis 83(1): 201-207, 2003

Cooperation needed to optimise cancer drug development. Lancet 363(9414): 1045, 2004

Alterations in processes and priorities needed for new drug development. Annals of Internal Medicine 145(10): 793-796, 2006

Path of least resistance. New drug development guidance needed from FDA. GmhcTreatmentIssues20(4-7):12, 2006

More collaboration needed between drug development and imaging communities. Drug Discovery Today 6(10): 514-515, 2001

Paradigm shift to address drug resistant tuberculosis in people living with HIV needed, and needed now. Tropical Medicine and International Health 14(4): 376-378, 2009

Model-based drug development: strengths, weaknesses, opportunities, and threats for broad application of pharmacometrics in drug development. Journal of Clinical Pharmacology 50(9 Suppl): 31s, 2010

An aide memoire for model-based drug development--a new key for the interpretation of the erythromycin breath test--therapeutic index as a biomarker for smart drug development. Biomarkers in Medicine 7(1): 89-91, 2013

Harmonization of Renal Function Assessment Is Needed Throughout the Whole Process of Anticancer Drug Development. Journal of Clinical Oncology 34(20): 2429-2430, 2016

The enabling technologies needed for PET-based molecular imaging to support drug development. Drug Discovery Today. Technologies 2(4): 305-309, 2005

What Is Needed to Eradicate Lymphatic Filariasis? A Model-Based Assessment on the Impact of Scaling Up Mass Drug Administration Programs. Plos Neglected Tropical Diseases 9(10): E0004147, 2015